Antigastric parietal cell and antithyroid autoantibodies in patients with recurrent aphthous stomatitis

Yang Che Wu, Yu Hsueh Wu, Yi Ping Wang, Julia Yu Fong Chang, Hsin Ming Chen, Andy Sun

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background/Purpose Anti-gastric parietal cell antibody (GPCA), anti-thyroglobulin antibody (TGA), and anti-thyroid microsomal antibody (TMA) have not yet been reported in patients with recurrent aphthous stomatitis (RAS). This study mainly assessed the frequencies of the presence of serum GPCA, TGA, and TMA in different types of RAS patients. Methods Serum GPCA, TGA, and TMA levels were measured in 355 RAS patients of different subtypes and in 355 age- and sex-matched healthy control individuals. Results We found that 13.0%, 19.4%, and 19.7% of 355 RAS patients, 16.7%, 23.3%, and 21.7% of 60 major-typed RAS patients, 12.2%, 18.6%, and 19.3% of 295 minor-typed RAS patients, 18.1%, 20.0%, and 21.9% of 160 atrophic glossitis-positive RAS (AG+/RAS) patients, and 8.7%, 19.0%, and 17.9% of 195 AG-negative RAS (AG–/RAS) patients had the presence of GPCA, TGA, and TMA in their sera, respectively. RAS, major-typed RAS, minor-typed RAS, AG+/RAS, and AG–/RAS patients all had a significantly higher frequency of GPCA, TGA, or TMA positivity than healthy control individuals (all p < 0.001). Of 65 TGA/TMA-positive RAS patients whose serum thyroid-stimulating hormone (TSH) levels were measured, 76.9%, 12.3%, and 10.8% of these TGA/TMA-positive RAS patients had normal, lower, and higher serum TSH levels, respectively. Conclusion We conclude that approximately one-third RAS patients may have GPCA/TGA/TMA positivity in their sera. Because some GPCA-positive patients may develop pernicious anemia, autoimmune atrophic gastritis, and gastric carcinoma, and some TGA/TMA-positive patients may have thyroid dysfunction such as hyperthyroidism and hypothyroidism, these patients should be referred to doctors for further management.

Original languageEnglish
Pages (from-to)4-9
Number of pages6
JournalJournal of the Formosan Medical Association
Volume116
Issue number1
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

Autoantibodies
Gastric Parietal Cells
Thyroglobulin
Antibodies
Serum
Sutton disease 2
Thyrotropin
Glossitis
thyroid microsomal antibodies
Atrophic Gastritis
Pernicious Anemia
Hyperthyroidism
Hypothyroidism
Stomach
Thyroid Gland

Keywords

  • antigastric parietal cell antibody
  • antithyroglobulin antibody
  • antithyroid microsomal antibody
  • atrophic glossitis
  • recurrent aphthous stomatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antigastric parietal cell and antithyroid autoantibodies in patients with recurrent aphthous stomatitis. / Wu, Yang Che; Wu, Yu Hsueh; Wang, Yi Ping; Chang, Julia Yu Fong; Chen, Hsin Ming; Sun, Andy.

In: Journal of the Formosan Medical Association, Vol. 116, No. 1, 01.01.2017, p. 4-9.

Research output: Contribution to journalArticle

Wu, Yang Che ; Wu, Yu Hsueh ; Wang, Yi Ping ; Chang, Julia Yu Fong ; Chen, Hsin Ming ; Sun, Andy. / Antigastric parietal cell and antithyroid autoantibodies in patients with recurrent aphthous stomatitis. In: Journal of the Formosan Medical Association. 2017 ; Vol. 116, No. 1. pp. 4-9.
@article{7184c93d6fe8415a8a59cd2015f5108c,
title = "Antigastric parietal cell and antithyroid autoantibodies in patients with recurrent aphthous stomatitis",
abstract = "Background/Purpose Anti-gastric parietal cell antibody (GPCA), anti-thyroglobulin antibody (TGA), and anti-thyroid microsomal antibody (TMA) have not yet been reported in patients with recurrent aphthous stomatitis (RAS). This study mainly assessed the frequencies of the presence of serum GPCA, TGA, and TMA in different types of RAS patients. Methods Serum GPCA, TGA, and TMA levels were measured in 355 RAS patients of different subtypes and in 355 age- and sex-matched healthy control individuals. Results We found that 13.0{\%}, 19.4{\%}, and 19.7{\%} of 355 RAS patients, 16.7{\%}, 23.3{\%}, and 21.7{\%} of 60 major-typed RAS patients, 12.2{\%}, 18.6{\%}, and 19.3{\%} of 295 minor-typed RAS patients, 18.1{\%}, 20.0{\%}, and 21.9{\%} of 160 atrophic glossitis-positive RAS (AG+/RAS) patients, and 8.7{\%}, 19.0{\%}, and 17.9{\%} of 195 AG-negative RAS (AG–/RAS) patients had the presence of GPCA, TGA, and TMA in their sera, respectively. RAS, major-typed RAS, minor-typed RAS, AG+/RAS, and AG–/RAS patients all had a significantly higher frequency of GPCA, TGA, or TMA positivity than healthy control individuals (all p < 0.001). Of 65 TGA/TMA-positive RAS patients whose serum thyroid-stimulating hormone (TSH) levels were measured, 76.9{\%}, 12.3{\%}, and 10.8{\%} of these TGA/TMA-positive RAS patients had normal, lower, and higher serum TSH levels, respectively. Conclusion We conclude that approximately one-third RAS patients may have GPCA/TGA/TMA positivity in their sera. Because some GPCA-positive patients may develop pernicious anemia, autoimmune atrophic gastritis, and gastric carcinoma, and some TGA/TMA-positive patients may have thyroid dysfunction such as hyperthyroidism and hypothyroidism, these patients should be referred to doctors for further management.",
keywords = "antigastric parietal cell antibody, antithyroglobulin antibody, antithyroid microsomal antibody, atrophic glossitis, recurrent aphthous stomatitis",
author = "Wu, {Yang Che} and Wu, {Yu Hsueh} and Wang, {Yi Ping} and Chang, {Julia Yu Fong} and Chen, {Hsin Ming} and Andy Sun",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2016.09.008",
language = "English",
volume = "116",
pages = "4--9",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Antigastric parietal cell and antithyroid autoantibodies in patients with recurrent aphthous stomatitis

AU - Wu, Yang Che

AU - Wu, Yu Hsueh

AU - Wang, Yi Ping

AU - Chang, Julia Yu Fong

AU - Chen, Hsin Ming

AU - Sun, Andy

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background/Purpose Anti-gastric parietal cell antibody (GPCA), anti-thyroglobulin antibody (TGA), and anti-thyroid microsomal antibody (TMA) have not yet been reported in patients with recurrent aphthous stomatitis (RAS). This study mainly assessed the frequencies of the presence of serum GPCA, TGA, and TMA in different types of RAS patients. Methods Serum GPCA, TGA, and TMA levels were measured in 355 RAS patients of different subtypes and in 355 age- and sex-matched healthy control individuals. Results We found that 13.0%, 19.4%, and 19.7% of 355 RAS patients, 16.7%, 23.3%, and 21.7% of 60 major-typed RAS patients, 12.2%, 18.6%, and 19.3% of 295 minor-typed RAS patients, 18.1%, 20.0%, and 21.9% of 160 atrophic glossitis-positive RAS (AG+/RAS) patients, and 8.7%, 19.0%, and 17.9% of 195 AG-negative RAS (AG–/RAS) patients had the presence of GPCA, TGA, and TMA in their sera, respectively. RAS, major-typed RAS, minor-typed RAS, AG+/RAS, and AG–/RAS patients all had a significantly higher frequency of GPCA, TGA, or TMA positivity than healthy control individuals (all p < 0.001). Of 65 TGA/TMA-positive RAS patients whose serum thyroid-stimulating hormone (TSH) levels were measured, 76.9%, 12.3%, and 10.8% of these TGA/TMA-positive RAS patients had normal, lower, and higher serum TSH levels, respectively. Conclusion We conclude that approximately one-third RAS patients may have GPCA/TGA/TMA positivity in their sera. Because some GPCA-positive patients may develop pernicious anemia, autoimmune atrophic gastritis, and gastric carcinoma, and some TGA/TMA-positive patients may have thyroid dysfunction such as hyperthyroidism and hypothyroidism, these patients should be referred to doctors for further management.

AB - Background/Purpose Anti-gastric parietal cell antibody (GPCA), anti-thyroglobulin antibody (TGA), and anti-thyroid microsomal antibody (TMA) have not yet been reported in patients with recurrent aphthous stomatitis (RAS). This study mainly assessed the frequencies of the presence of serum GPCA, TGA, and TMA in different types of RAS patients. Methods Serum GPCA, TGA, and TMA levels were measured in 355 RAS patients of different subtypes and in 355 age- and sex-matched healthy control individuals. Results We found that 13.0%, 19.4%, and 19.7% of 355 RAS patients, 16.7%, 23.3%, and 21.7% of 60 major-typed RAS patients, 12.2%, 18.6%, and 19.3% of 295 minor-typed RAS patients, 18.1%, 20.0%, and 21.9% of 160 atrophic glossitis-positive RAS (AG+/RAS) patients, and 8.7%, 19.0%, and 17.9% of 195 AG-negative RAS (AG–/RAS) patients had the presence of GPCA, TGA, and TMA in their sera, respectively. RAS, major-typed RAS, minor-typed RAS, AG+/RAS, and AG–/RAS patients all had a significantly higher frequency of GPCA, TGA, or TMA positivity than healthy control individuals (all p < 0.001). Of 65 TGA/TMA-positive RAS patients whose serum thyroid-stimulating hormone (TSH) levels were measured, 76.9%, 12.3%, and 10.8% of these TGA/TMA-positive RAS patients had normal, lower, and higher serum TSH levels, respectively. Conclusion We conclude that approximately one-third RAS patients may have GPCA/TGA/TMA positivity in their sera. Because some GPCA-positive patients may develop pernicious anemia, autoimmune atrophic gastritis, and gastric carcinoma, and some TGA/TMA-positive patients may have thyroid dysfunction such as hyperthyroidism and hypothyroidism, these patients should be referred to doctors for further management.

KW - antigastric parietal cell antibody

KW - antithyroglobulin antibody

KW - antithyroid microsomal antibody

KW - atrophic glossitis

KW - recurrent aphthous stomatitis

UR - http://www.scopus.com/inward/record.url?scp=85002923154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002923154&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2016.09.008

DO - 10.1016/j.jfma.2016.09.008

M3 - Article

C2 - 27793414

AN - SCOPUS:85002923154

VL - 116

SP - 4

EP - 9

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 1

ER -